Arthur He
Stock Analyst at HC Wainwright & Co.
(0.68)
# 3,763
Out of 4,829 analysts
61
Total ratings
23.21%
Success rate
-27.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Assumes: Buy | $75 | $21.71 | +245.46% | 1 | May 5, 2025 | |
| ADAG Adagene | Reiterates: Buy | $8 | $1.60 | +400.00% | 10 | Apr 3, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $3.5 → $3 | $0.29 | +925.29% | 6 | Apr 1, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.43 | - | 8 | Mar 31, 2025 | |
| LVTX LAVA Therapeutics | Reiterates: Neutral | $1.5 | $1.25 | +20.00% | 10 | Mar 31, 2025 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $1.30 | +669.23% | 7 | Mar 19, 2025 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $6.5 | $0.59 | +1,004.13% | 3 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 → $20 | $2.76 | +624.64% | 9 | Mar 10, 2025 | |
| HOOK HOOKIPA Pharma | Downgrades: Neutral | n/a | $1.30 | - | 7 | Jan 10, 2025 |
Vera Therapeutics
May 5, 2025
Assumes: Buy
Price Target: $75
Current: $21.71
Upside: +245.46%
Adagene
Apr 3, 2025
Reiterates: Buy
Price Target: $8
Current: $1.60
Upside: +400.00%
Adaptimmune Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $0.29
Upside: +925.29%
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.43
Upside: -
LAVA Therapeutics
Mar 31, 2025
Reiterates: Neutral
Price Target: $1.5
Current: $1.25
Upside: +20.00%
Prime Medicine
Mar 19, 2025
Reiterates: Buy
Price Target: $10
Current: $1.30
Upside: +669.23%
Nektar Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $6.5
Current: $0.59
Upside: +1,004.13%
Solid Biosciences
Mar 10, 2025
Maintains: Buy
Price Target: $16 → $20
Current: $2.76
Upside: +624.64%
HOOKIPA Pharma
Jan 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.30
Upside: -